Welcure Drugs & Pharmaceuticals Limited
BSE: WELCURE
Prev Close
0.35
Open Price
0.35
Volume
57,084,064
Today Low / High
0.34 / 0.36
52 WK Low / High
0.28 / 1.44455
Range
0 - 0
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 0.34, reflecting a change of -0.01 (-2.85714%). The expected target range on the BSE is 0 - 0. The stock is showing a downward trend on the BSE. This could indicate a potential risk for investors who are considering buying at this moment.
Welcure Drugs & Pharmaceuticals Limited Graph
Welcure Drugs & Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Welcure Drugs & Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 0.34, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 0.34 | 0.34 | 0.31 - 0.38 |
| 0.35 | 0.28 - 0.42 | ||
| 0.35 | 0.25 - 0.46 | ||
| Bearish Scenario | 0.34 | 0.34 | 0.30 - 0.37 |
| 0.33 | 0.27 - 0.40 | ||
| 0.33 | 0.23 - 0.43 |
Overview of Welcure Drugs & Pharmaceuticals Limited
ISIN
INE331C01025
Industry
Medical - Pharmaceuticals
Vol.Avg
12,151,651
Market Cap
39,325,370
Last Dividend
0
Official Website
IPO Date
2000-11-27
DCF Diff
13.23
DCF
-5
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 24.55 Cr | 20.79 Cr | 3.76 Cr | 0.1533 | 0.00 Cr | 2.02 Cr | 0.87 Cr | 2.17 Cr | 0.19 | 2.79 Cr | 0.0884 |
| 2024-03-31 | 0.00 Cr | 0.04 Cr | -0.04 Cr | 0.0000 | 0.00 Cr | 0.00 Cr | -0.18 Cr | -0.18 Cr | -0.13 | -0.14 Cr | 0.0000 |
| 2023-03-31 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.0000 | 0.00 Cr | 0.03 Cr | 0.04 Cr | 0.10 Cr | 0.08 | 0.11 Cr | 0.0000 |
| 2022-03-31 | 0.11 Cr | 0.00 Cr | 0.11 Cr | 1.0000 | 0.00 Cr | 0.02 Cr | 0.02 Cr | 0.02 Cr | 0.02 | 0.02 Cr | 0.2246 |
| 2021-03-31 | 0.13 Cr | 0.00 Cr | 0.13 Cr | 1.0000 | 0.00 Cr | 0.02 Cr | 0.06 Cr | 0.06 Cr | 0.05 | 0.06 Cr | 0.4136 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.13 Cr | 266.98 Cr | 164.47 Cr | 102.5105 Cr | 123.20 Cr | 123.07 Cr | 143.52 Cr | 0.03 Cr | 0.00 Cr | 0.00 Cr | 84.73 Cr | 41.2688 Cr |
| 2024-03-31 | 0.02 Cr | 1.37 Cr | 0.03 Cr | 1.3404 Cr | 0.00 Cr | -0.02 Cr | 0.00 Cr | 0.02 Cr | 0.00 Cr | 0.00 Cr | 1.29 Cr | 0.0306 Cr |
| 2023-03-31 | 0.00 Cr | 1.53 Cr | 0.01 Cr | 1.5153 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.06 Cr | 0.00 Cr | 0.00 Cr | 0.17 Cr | 0.0136 Cr |
| 2022-03-31 | 0.07 Cr | 0.10 Cr | 0.00 Cr | 0.0930 Cr | 0.00 Cr | -0.07 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.0038 Cr |
| 2021-03-31 | 0.05 Cr | 0.07 Cr | 0.00 Cr | 0.0694 Cr | 0.00 Cr | -0.05 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 1.39 Cr | 0.0036 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -222.0082 Cr | -0.0635 Cr | 222.1989 Cr | -222.0252 Cr | 0.1067 Cr | 0.1283 Cr | -0.0635 Cr | 2.1701 Cr | 123.1989 Cr | 0.0000 Cr | -143.5236 Cr |
| 2024-03-31 | -0.1276 Cr | 0.1650 Cr | -0.0171 Cr | -0.1276 Cr | 0.0204 Cr | 0.0216 Cr | 0.0000 Cr | -0.1750 Cr | -0.0171 Cr | 0.0000 Cr | 0.0000 Cr |
| 2023-03-31 | 0.1069 Cr | 1.3205 Cr | -1.4922 Cr | 0.1069 Cr | -0.0648 Cr | 0.0012 Cr | 0.0000 Cr | 0.1017 Cr | -1.4922 Cr | 0.0000 Cr | 0.0000 Cr |
| 2022-03-31 | 0.0186 Cr | 0.0000 Cr | 0.0000 Cr | 0.0186 Cr | 0.0186 Cr | 0.0660 Cr | 0.0000 Cr | 0.0236 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr |
| 2021-03-31 | 0.0422 Cr | 0.0000 Cr | 0.0000 Cr | 0.0422 Cr | 0.0422 Cr | 0.0475 Cr | 0.0000 Cr | 0.0551 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 0.00 Cr | 0.01 Cr | -0.01 Cr | 0.0000 | -0.04 Cr | 1.07 Cr | 0.01 | -0.03 Cr | 0.0000 |
| 2025-09-30 | 65.62 Cr | 54.13 Cr | 11.49 Cr | 0.1751 | 11.36 Cr | 8.50 Cr | 0.07 | 11.37 Cr | 0.1296 |
| 2025-06-30 | 299.91 Cr | 268.72 Cr | 31.20 Cr | 0.1040 | 31.14 Cr | 23.30 Cr | 2.07 | 31.14 Cr | 0.0777 |
| 2025-03-31 | 21.21 Cr | 17.97 Cr | 3.24 Cr | 0.1527 | 0.63 Cr | 2.54 Cr | 0.23 | 2.55 Cr | 0.1197 |
| 2024-12-31 | 8.84 Cr | 7.38 Cr | 1.46 Cr | 0.1648 | 0.91 Cr | 0.41 Cr | 0.04 | 0.92 Cr | 0.0469 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 0.12 Cr | 0.00 Cr | 0.12 Cr | 384.49 Cr | 143.52 Cr | 548.05 Cr | 0.02 Cr | 632.89 Cr | 498.58 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 0.13 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -102.51 Cr |
| 2025-03-31 | 0.13 Cr | 0.00 Cr | 0.13 Cr | 18.97 Cr | 143.52 Cr | 182.14 Cr | 0.03 Cr | 266.98 Cr | 164.47 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 0.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -101.83 Cr |
| 2024-09-30 | 0.23 Cr | 0.00 Cr | 0.23 Cr | 33.17 Cr | 143.52 Cr | 268.42 Cr | 0.03 Cr | 269.84 Cr | 168.01 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 0.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 1.84 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -0.35 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Medical - Pharmaceuticals
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| MedPlus Health Services Limited | MEDPLUS | ₹835.05 | ₹100,208,823,304.00 | ₹147,497.00 |
Key Executives
Gender: male
Year Born:
Gender: female
Year Born:
FAQs about Welcure Drugs & Pharmaceuticals Limited
The CEO is Chintan Didawala Ganpat.
The current price is ₹0.35.
The range is ₹0.28-1.44455.
The market capitalization is ₹3.93 crores.
The P/E ratio is 1.22.
The company operates in the Healthcare sector.
Overview of Welcure Drugs & Pharmaceuticals Limited (ISIN: INE331C01025) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹3.93 crores and an average daily volume of 12,151,651 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.